NEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, researchers ...

A study comparing a new, higher-dose nasal spray for opioid overdoses to the standard dose found no increase in survival rates but more side effects. The 8-milligram naloxone spray, approved two years ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. U.S. regulators on Friday approved the first ...

FILE - This image provided by Hikma Pharmaceuticals shows the company's nasal spray drug Kloxxado, containing 8 milligrams of naloxone. A study published Thursday, Feb. 8, 2024 finds that a new, ...

U.S. regulators on Friday approved the first high-dose nasal spray for reversing opioid overdoses. The Food and Drug Administration approved Hikma Pharmaceuticals’ Kloxxado, a spray containing 8 ...

NEW YORKNEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, ...